BioSpace News Archive

Biocept, Inc . (NASDAQ: BIOC), a leading provider of molecular diagnostic assays and services, has been awarded a South Korean Patent for its Primer-Switch technology.

Avinger, Inc. today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for a new Pantheris clinical indication for the treatment of in-stent restenosis (ISR) in the lower extremity arteries.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, announced that management will participate in the following upcoming virtual investor conferences:

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET.

Recent guidance by the FDA and EMA (E6 (R2) Good Clinical Practice) emphasizes the need for education and training of all constituents in a clinical trial to reduce unwanted protocol deviations and improve overall quality in clinical trial operations.

Vivera Pharmaceuticals, Inc., congratulates its clinical research partner, Parexel International, on its $8.5 billion acquisition.

Fresenius Kabi announced today the U.S. introduction of Fentanyl Citrate Injection, USP 50 mcg per 1 mL in its proprietary Simplist ® ready-to-administer prefilled syringe.

Arcturus Therapeutics Holdings Inc. announced that the Company will participate in upcoming investor and scientific conferences.

Avantor, Inc. announced that it will release its financial results for the second quarter 2021 after the market closes on Wednesday, July 28, 2021.

NRx today announced it is initiating clinical training of Nation of Georgia (Georgia) ICU physicians, in the use of intravenous ZYESAMI™ (Aviptadil- acetate) for emergency use in patients suffering with Critical COVID-19, and inhaled ZYESAMI™ for use in phase 2/3 clinical trials, for patients suffering with COVID-19.